88 articles
ACR246
ACR246 (ACR-246, ADC2154) is an anti-5T4 antibody-drug conjugate with a topoisomerase I inhibitor payload D-2102, DAR 8, developed by Hangzhou Adcoris Biopharma; in Phase I/IIa trials in China and licensed globally to K2 Therapeutics in 2026.
Albusomatropin
Albusomatropin (TV-1106, Albutropin) is an 88 kDa human serum albumin-human growth hormone fusion protein developed by Teva as a once-weekly growth hormone; development was discontinued in 2016 after neutralizing antibodies appeared in a pediatric phase 2 trial.
Anbenitamab repodatecan
Anbenitamab repodatecan (development code JSKN003) is an antibody-drug conjugate against HER2, developed by Alphamab Oncology and in phase III trials for breast, ovarian, and colorectal cancers.
Andecaliximab
Andecaliximab (GS-5745), a Gilead-developed humanized IgG4 monoclonal antibody inhibiting MMP-9, failed phase 2/3 trials in ulcerative colitis, Crohn's disease, and gastric cancer (GAMMA-1), and is now in the ANDECAL trial for fibrodysplasia ossificans progressiva.
Anifrolumab
Anifrolumab (Saphnelo, formerly MEDI-546) is AstraZeneca's fully human anti-IFNAR1 monoclonal antibody blocking all type I interferons, FDA-approved in 2021 as add-on therapy for moderate-to-severe systemic lupus erythematosus.
Arcotatug tavatecan
Arcotatug tavatecan (research code IBI343; Takeda development code TAK-921) is an antibody–drug conjugate developed by Innovent Biologics for CLDN18.2-positive gastric, gastroesophageal junction, and pancreatic cancers.
ATG-106
ATG-106 is Antengene's preclinical "2+1" sterically masked CDH6 x CD3 bispecific T-cell engager for ovarian and kidney cancer, licensed in June 2026 to MPM BioImpact-established K2 Therapeutics for about $20 million upfront plus up to $960.5 million in milestones, ex-Greater China.
Balstilimab
Balstilimab (AGEN-2034) is Agenus's fully human IgG4 anti-PD-1 checkpoint inhibitor investigated in cervical cancer alone or with zalifrelimab, and with botensilimab in colorectal, pancreatic, ovarian, and renal cancers.
Becotatug vedotin
Becotatug vedotin (MRG003, MEIYOUHENG) is an EGFR-targeted antibody-drug conjugate of JMT101 plus MMAE, approved in China in 2025 for recurrent/metastatic nasopharyngeal carcinoma, with phase IIa ORR 42%.
Belantamab mafodotin
Belantamab mafodotin (belamaf, Blenrep, GSK2857916) is a first-in-class BCMA-targeting antibody-drug conjugate with MMAF payload for multiple myeloma; approved 2020, withdrawn 2023, reapproved 2025; hallmark toxicity is keratopathy.
Belumosudil
Belumosudil (Rezurock) is an oral selective ROCK2 inhibitor approved in 2021 for chronic graft-versus-host disease after at least two failed systemic therapy lines, combining immunomodulatory and antifibrotic actions.
Belzupacap sarotalocan
Belzupacap sarotalocan (bel-sar, AU-011) is Aura Biosciences' investigational virus-like drug conjugate of HPV-derived VLPs conjugated to IR700 dye, activated by 689 nm near-infrared light to kill HSPG-expressing tumor cells; in phase 3 for choroidal melanoma.
Bococizumab
Bococizumab (PF-04950615, RN316) was Pfizer's humanized anti-PCSK9 monoclonal antibody that lowered LDL cholesterol about 56% but was discontinued in 2016 after antidrug antibodies attenuated its effect and SPIRE outcome trials failed.
BSI-060T (PYX-106, anti-Siglec-15)
BSI-060T (PYX-106, aldastotug) is a fully human IgG1 anti-Siglec-15 antibody licensed by Pyxis Oncology from Biosion in 2022; its Phase 1 solid tumor trial was paused in December 2024 and the license terminated effective August 2026.
CBP-1018, bi-ligand drug conjugate
CBP-1018 (MVB-101), Coherent Biopharma's Bi-XDC bispecific peptide-drug conjugate targeting PSMA and FRalpha with an MMAE payload, in phase I/II trials for metastatic castration-resistant prostate cancer; licensed ex-Greater China to MultiValent Biotherapies for up to about USD 2 billion.
Click-to-release antibody–drug conjugates
Click-to-release antibody–drug conjugates, or click-cleavable ADCs, are ADCs whose payload is released extracellularly by a separate tetrazine trigger, extending therapy to non-internalizing targets; introduced in 2013.
CMG1A46
CMG1A46 (1A46) is Chimagen Biosciences' IgG-like CD19/CD20/CD3 trispecific T-cell engager on the TRIAD platform, acquired by GSK in 2024 for $300 million upfront, in trials for B-cell lymphoma, leukemia, and lupus.
CMG901 (Claudin 18.2 ADC)
CMG901, also known as AZD0901 or sonesitatug vedotin, is an antibody–drug conjugate targeting Claudin 18.2, discovered by Keymed Biosciences and licensed to AstraZeneca for gastric, gastroesophageal junction, and pancreatic cancers.
Condoliase
Condoliase (SI-6603, HERNICORE), chondroitin sulfate ABC endolyase from Proteus vulgaris, is an enzyme injected into the disc for chemonucleolysis of lumbar disc herniation; approved in Japan in 2018, single 1.25 U dose, 78% effective rate, 9% proceed to surgery.
Datopotamab deruxtecan
Datopotamab deruxtecan (Dato-DXd, DS-1062a, Datroway) is a TROP2-directed antibody-drug conjugate with a DXd topoisomerase I inhibitor payload, approved in the US for EGFR-mutated NSCLC, TNBC, and HR-positive HER2-negative breast cancer, and in the EU for breast cancer.
DB-1418, EGFR/HER3 bispecific antibody-drug conjugate
DB-1418 (AVZO-1418) is DualityBio's EGFR/HER3 bispecific antibody-drug conjugate with a topoisomerase I inhibitor payload (DAR 6), licensed to Avenzo Therapeutics ex-Greater China, in the AVENTINE-1 Phase 1/2 trial with FDA Fast Track for EGFR-mutant TKI-pretreated NSCLC.
Disitamab vedotin
Disitamab vedotin, sold as Aidexi and code-named RC48, is an antibody–drug conjugate targeting HER2, developed by RemeGen and first approved in China in 2021 for gastric cancer.
Eladocagene exuparvovec
Eladocagene exuparvovec (Upstaza, Kebilidi) is a PTC Therapeutics AAV2 gene therapy delivering the DDC gene for AADC deficiency, approved in the EU in 2022 and by FDA in 2024.
Elfetabart drozuntecan
DB-1311 (BNT324, elfetabart drozuntecan) is a DualityBio-discovered, BioNTech-partnered antibody-drug conjugate targeting B7-H3 with a topoisomerase-I inhibitor payload P1021, in phase 3 development for metastatic castration-resistant prostate cancer.
Emicizumab
Emicizumab (Hemlibra, ACE 910) is a subcutaneous bispecific IgG4 antibody bridging FIXa and FX to mimic factor VIIIa for hemophilia A prophylaxis, with or without FVIII inhibitors; HAVEN trials showed 87-97% bleeding-rate reductions.
Enfortumab vedotin
Enfortumab vedotin (Padcev, enfortumab vedotin-ejfv), a nectin-4-targeted antibody-drug conjugate for urothelial bladder cancer; FDA approved 2019; EV-301 and EV-302 survival results; boxed skin-reaction warning.
Ersodetug
Ersodetug (RZ358, XOMA 358) is Rezolute's investigational fully human IgG2 monoclonal antibody, a negative allosteric modulator of the insulin receptor, in Phase 3 trials for congenital and tumor hyperinsulinism hypoglycemia; not yet approved.
Etirinotecan pegol
Etirinotecan pegol (NKTR-102, brand name Onzeald) is an investigational, long-acting PEGylated conjugate of the topoisomerase I inhibitor irinotecan, designed to release irinotecan slowly for sustained tumor exposure.
Galiximab
Galiximab (IDEC-114), a discontinued primatized anti-CD80 (B7-1) IgG1 lambda monoclonal antibody with macaque variable regions, was trialed in follicular and Hodgkin lymphoma, alone and with rituximab.
Garetatug rezetecan
Garetatug rezetecan (SHR-A1904, 瑞康戈芮妥塔单抗) is a Hengrui anti-CLDN18.2 antibody-drug conjugate carrying the topoisomerase I inhibitor rezetecan, in phase III trials for CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma.